Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria
Panelists discuss how patient selection criteria for second-line chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma encompass both clinical eligibility guidelines and practical considerations, including geographical and financial factors.
EP: 1.Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM
EP: 2.Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?
EP: 3.Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria
EP: 4.University of Kansas Medical Center Insights: CAR T Referral Process
EP: 5.Reviewing CAR T Mechanism & Treatment Process
EP: 6.Approaches to Bridging Therapy During the CAR T Manufacturing Process
EP: 7.Comanaging Cases of RR/MM in Patients Receiving CAR T
EP: 8.On-going Clinical Trials With CAR T Therapy in Earlier-Line Multiple Myeloma Treatment: Future Perspectives
EP: 9.Expert Insights: 68yM High-Risk R/R MM Post HSCT With Progressive Disease—Next Steps?
EP: 10.Expert Insights: Key Takeaways & Clinical Pearls on CAR T Therapy in R/R MM
Video content above is prompted by the following:
- Which patients do you think about for chimeric antigen receptor (CAR) T-cell therapy in second-line treatment for relapsed/refractory multiple myeloma (ciltacabtagene autoleucel vs idecabtagene vicleucel)?
- Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR T-cell therapy referral?
- How do nonmedical factors (location, money, etc) affect patient selection?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
